Cellyan Biotechnology has regained compliance with Nasdaq's minimum bid price requirement after meeting criteria for 14 consecutive days.
Quiver AI Summary
Cellyan Biotechnology Co., Ltd, a provider of OTC pharmaceutical e-commerce supply chain services in Hong Kong, announced it has regained compliance with Nasdaq's minimum bid price requirement. The company received written notification from Nasdaq on November 13, 2026, confirming that its Class A ordinary shares had maintained a closing bid price of at least $1.00 for 14 consecutive business days, thus satisfying the criteria for continued listing. This compliance comes after an earlier notification on January 12, 2026, regarding the stock price falling below the required threshold. Cellyan operates through subsidiaries that specialize in facilitating access to OTC pharmaceutical products for customers in Mainland China, offering a wide range of logistics and procurement services.
Potential Positives
- The company has regained compliance with Nasdaq's minimum bid price requirement, which is essential for its continued listing on the Nasdaq Capital Market.
- This compliance demonstrates improved financial performance, as the company's shares maintained a closing bid price of over US$1.00 for the necessary period.
- The extension granted by Nasdaq shows a supportive relationship and acknowledgment of the company's efforts to align with listing requirements.
- Regaining compliance may bolster investor confidence and attract further interest from potential investors, enhancing the company's market presence.
Potential Negatives
- The press release highlights that the company was previously non-compliant with Nasdaq's minimum bid price requirement, indicating potential financial instability and investor concern.
- The company had to go through an extended compliance period, which could signal ongoing challenges in maintaining investor confidence and share value.
- The notification of prior non-compliance could negatively impact perceptions of the company's financial health and stability among investors and stakeholders.
FAQ
What compliance requirement did Cellyan Biotechnology meet?
Cellyan Biotechnology has regained compliance with Nasdaq's minimum bid price requirement for continued listing.
When did Nasdaq notify Cellyan Biotechnology about non-compliance?
Nasdaq notified Cellyan Biotechnology on January 12, 2026, about the non-compliance with the minimum bid price requirement.
How long was Cellyan Biotechnology given to regain compliance?
Cellyan Biotechnology was initially given 180 calendar days, extendable by another 180 days if necessary, to regain compliance.
What was the required share price to regain compliance?
The required closing bid price to regain compliance was at least US$1.00 per share for a minimum of 10 consecutive days.
What services does Cellyan Biotechnology offer?
Cellyan Biotechnology offers OTC pharmaceutical cross-border e-commerce supply chain services and procurement and distribution through its subsidiaries.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$HKPD Hedge Fund Activity
We have seen 4 institutional investors add shares of $HKPD stock to their portfolio, and 3 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- STONEX GROUP INC. removed 95,695 shares (-93.5%) from their portfolio in Q3 2026, for an estimated $222,012
- XTX TOPCO LTD added 38,930 shares (+inf%) to their portfolio in Q2 2026, for an estimated $14,793
- TWO SIGMA INVESTMENTS, LP removed 10,832 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $4,116
- HRT FINANCIAL LP added 2,943 shares (+140.7%) to their portfolio in Q3 2026, for an estimated $6,827
- JANE STREET GROUP, LLC added 1,636 shares (+66.7%) to their portfolio in Q3 2026, for an estimated $3,795
- UBS GROUP AG removed 54 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $125
- JPMORGAN CHASE & CO added 6 shares (+inf%) to their portfolio in Q3 2026, for an estimated $13
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
Hong Kong, China, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the “ Company ”), a leading provider of over-the-counter (“OTC”) pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced that it received written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) on November 13, 2026, confirming that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “ Minimum Bid Price Requirement ”) for continued listing on the Nasdaq Capital Market.
As previously announced, on January 12, 2026, Nasdaq notified the Company that the closing bid price of the Company’s Class A ordinary shares had been below US$1.00 per share for 30 consecutive business days and that, as a result, the Company was not in compliance with the Minimum Bid Price Requirement. Nasdaq provided the Company with an initial compliance period of 180 calendar days, or until July 13, 2026, to regain compliance. To regain compliance, the Company was required to maintain a closing bid price of at least US$1.00 per share for a minimum of 10 consecutive business days during the compliance period. On July 14, 2026, the Company received written notice from Nasdaq granting an additional 180 calendar days, or until January 11, 2027, to regain compliance with the Minimum Bid Price Requirement.
Subsequently, on November 13, 2026, Nasdaq determined that the closing bid price of the Company’s Class A ordinary shares was at least US$1.00 per share for the 14 consecutive business days from October 26 through November 12, 2026. Accordingly, the Company has regained compliance with the Minimum Bid Price Requirement, and the matter was closed.
About Cellyan Biotechnology Co., Ltd
Cellyan Biotechnology Co., Ltd (f.k.a. Hong Kong Pharma Digital Technology Holdings Limited) offers two main categories of services: (i) OTC pharmaceutical cross-border e-commerce supply chain services through its Hong Kong subsidiary, Joint Cross Border Logistics Company Limited (“Joint Cross Border”), and (ii) OTC pharmaceutical cross-border procurement and distribution through its Hong Kong subsidiary, V-Alliance Technology Supplies Limited.
Through its engagement with OTC pharmaceutical suppliers, logistics companies, and merchants on Chinese e-commerce platforms, Joint Cross Border provides a convenient one-stop solution for Mainland Chinese customers seeking access to OTC pharmaceutical products outside Mainland China. Joint Cross Border’s comprehensive service offerings include pre-consultation, product information review, procuring overseas OTC pharmaceutical products, enlisting products with the Hong Kong Department of Health, obtaining import and export permits, storing products, packaging, and arranging logistics and end-to-end delivery services for customers.
For investor and media inquiries please contact:
Cellyan Biotechnology Co., Ltd
Media Contact:
[email protected]
Investor Relations:
[email protected]